Clinical trials: Anticoagulant
Leg Injuries, Winter Sport Resorts
Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort
The purpose of this study is to evaluate the impact of thromboembolic diseases and heparin complications in patients with a lower limb trauma supported by physicians of mountain.
- Conditions
- Leg Injuries, Winter Sport Resorts, Outpatients
- Trial name
- M2M-Thrombose (NCT01303523)
- Where
- 28 sites in France
- Volunteers
- 1,627 people
- Sponsor
- Floralis
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Subdural Hematoma, Atrial Fibrillation (AF)
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural…
- Trial name
- RELACS (NCT06696079)
- Testing
- Early Resumption of Oral Anticoagulation Therapy, Late Resumption of Oral Anticoagulation Therapy
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 332 people
- Sponsor
- Rahul Raj
Acute Ischemic Stroke
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
The study will randomize patients with acute ischemic stroke and Direct Oral AntiCoagulants (DOAC) ingestion within 48 hours from enrollment (but otherwise eligible for thrombolysis) to administration of intravenous tenecteplase…
- Trial name
- ESTER-DOAC (NCT07621796)
- Testing
- Intravenous tenecteplase (TNK)
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- Hackensack Meridian Health
Drug Interaction
The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
This study aims to determine the nature and significance of the theoretical drug interaction between enzalutamide (a drug used to treat prostate cancer) and the direct-acting oral anticoagulant drugs (DOACs).
- Trial name
- ENZA-D (NCT03920566)
- Testing
- Anti-Xa level
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Atrial Fibrillation, Obesity
Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation
In this study, the investigators evaluated the association between various measures of adiposity [BMI and waist circumference (WC)] and clinical outcomes in Asian patients with AF who were prescribed OAC, using a nationwide…
- Conditions
- Atrial Fibrillation, Obesity, Prognosis, Anticoagulants
- Trial name
- Paradox (NCT05645913)
- Testing
- Oral anticoagulant
- Where
- South Korea
- Volunteers
- 56,272 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Epistaxis
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal
This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal.
- Trial name
- Epistaxis (NCT06906861)
- Where
- Nepal
- Volunteers
- 284 people
- Sponsor
- Institute of medicine, Maharagjung medical campus
Atrial Fibrillation, Anticoagulant-induced Bleeding
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.
- Trial name
- MAS (NCT03803579)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Arianna Anticoagulazione Foundation
Venous Thromboembolism, Atrial Fibrillation
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
The arrival on the market of direct oral factor Xa and factor IIa inhibitors (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and others soon to come) raises novel questions among clinicians confronted with the…
- Trial name
- GIHP-NACO (NCT02185027)
- Testing
- complications and compliance with GIHP recommendations
- Where
- 41 sites in Belgium, France
- Volunteers
- 1,166 people
- Sponsor
- University Hospital, Grenoble
Atrial Fibrillation
Anticoagulants Comparative Benefit-risk Ratio in Real Life
The study is an analysis using the French national health insurance database, six months after the beginning of NOAC launch in the NVAF indication.
- Trial name
- NCT02785354
- Where
- France
- Volunteers
- 103,101 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Diseases
Stroke Prevention and Rhythm Interventions in Atrial Fibrillation
This observational registry will characterize contemporary stroke prevention in Canadian adults with atrial fibrillation, and provide clarity in understanding physician preferences for the various oral anticoagulants available in…
- Trial name
- SPRINT-AF (NCT01733160)
- Where
- Canada
- Volunteers
- 2,499 people
- Sponsor
- Canadian Collaborative Research Network
Head and Neck Cancer, Intraoperative Complications
Coagulation and Vitamin K in Head and Neck Microvascular Free Flap Surgery
For patients with large head and neck tumors the recommended treatment, in many cases, is a combination of extensive surgery and postoperative radiotherapy.
- Conditions
- Head and Neck Cancer, Intraoperative Complications, Coagulation Disorder, Blood, Vitamin K Deficiency
- Trial name
- MVL-COAG (NCT04517461)
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Region Skane
Anticoagulant
A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
This study will be a single-center, randomized, single-dose, open-label, two-treatment, two-period, two-sequence crossover bioequivalence study to compare the rate and extent of absorption of WD-1602 granule formulation (WD…
- Trial name
- NCT04592822
- Testing
- WD-1602, Pradaxa®
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Fibrillation, Atrial
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
The purpose of this study is to test whether Fondaparinux is effective and safe to prevent thromboembolic events (like for example strokes) and bleeding events in patients who undergo a normalisation of their heart rhythm…
- Trial name
- NCT00911300
- Testing
- fondaparinux, unfractionated heparin, Vitamin-K-Antagonist
- Where
- 34 sites in France, Germany
- Volunteers
- 349 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Concentration and Clinical Outcomes.
Introduction: Non-vitamin K antagonist oral anticoagulants (NOAC) is the first line therapy to prevent ischemic stroke or systemic thromboembolism among atrial fibrillation (AF) patients.
- Trial name
- NCT05333666
- Testing
- Data collection
- Where
- 2 sites in Taiwan
- Volunteers
- 1,500 people
- Sponsor
- National Taiwan University Hospital
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551730
- Testing
- PRT064445/Enoxaparin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Deep Venous Thrombosis
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
- Trial name
- NCT06913595
- Testing
- Direct Oral Anticoagulant., Low Molecular Weight Heparine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University